Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Neurology Clinical Team Leader Departure May Be Mountain Disguised As Molehill

Executive Summary

Attention to the departure of neurology reviewer Ron Farkas from FDA has focused on what it means for Sarepta’s eteplirsen application, but there are larger regulatory environment issues that deserve more scrutiny.

You may also be interested in...



Translarna AdCom Has DMD Experience, But Most Opposed Approval Of Prior Applications

Several members of the Peripheral and Central Nervous System Drugs Advisory Committee meeting looking at PTC' Therapeutics' proposed Duchenne muscular dystrophy treatment also looked at Sarepta's Exondys 51 and BioMarin's Kyndrisa, but most did not vote or comment favorably.

Sarepta Complained To Woodcock About Exondys 51 Review Early And Often

Documents also show that Sarepta officials begged CDER director for approval on multiple occasions prior to the agency's September 2016 decision.

Jenkins' Retirement From US FDA Was Several Years In The Making

Outgoing Office of New Drugs director dismisses speculation that his decision to leave the agency was related to events surrounding Sarepta's controversial Exondys 51 approval.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS119137

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel